tiprankstipranks
AbbVie (ABBV)
NYSE:ABBV

AbbVie Stock Forecast & Price Target

17,446 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
12Ratings
7 Buy
4 Hold
1 Sell
Based on 12 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABBV Stock Price Prediction

Average Price Target

$160.50
▲(11.98% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $160.50 with a high forecast of $188.00 and a low forecast of $135.00. The average price target represents a 11.98% change from the last price of $143.33.
Highest Price Target$188.00Average Price Target$160.50Lowest Price Target$135.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Truist Financial
$160.00
Buy
11.63%
Upside
Reiterated
Truist Securities reiterates Buy Rating on Abbvie (ABBV) Despite Humira Erosion, With Focus on Skyrizi/RinvoqTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $160.00 price target on Abbvie (NYSE: ABBV) following results, which has shares down 4% with the near-term focus on Humira erosion.
Berenberg Bank
$135.00
Hold
-5.81%
Downside
Reiterated
Berenberg Bank Maintains a Hold Rating on AbbVie (ABBV)
Bank of America Securities
$156.00
Hold
8.84%
Upside
Reiterated
Abbvie (ABBV) CFO Call Takeaways - BofA SecuritiesBofA Securities analyst Geoff Meacham reiterated a Neutral rating and $156.00 price target on Abbvie (NYSE: ABBV) after hosting AbbVies CEO Rick Gonzalez and CFO Rob Michael for a discussion on growth opportunities.
Daiwa
$150.00
Hold
4.65%
Upside
Downgraded
AbbVie downgraded to Neutral from Outperform at DaiwaAbbVie downgraded to Neutral from Outperform at Daiwa
Evercore ISI
$153.00
Buy
6.75%
Upside
Reiterated
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), AbbVie (ABBV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is $160.50.
    What is ABBV’s upside potential, based on the analysts’ average price target?
    AbbVie has 11.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABBV a Buy, Sell or Hold?
          AbbVie has a conensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 1 sell ratings.
            What is AbbVie’s price target?
            The average price target for AbbVie is $160.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $188.00 ,the lowest forecast is $135.00. The average price target represents 11.98% Increase from the current price of $143.33.
              What do analysts say about AbbVie?
              AbbVie’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis